Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer

MENLO PARK, Calif. and BOSTON — Adicet Bio, Inc., (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Don Healey, Ph.D., as Chief Technology Officer. Dr. Healey will lead the development of Adicet’s genetically-modified T cell therapies for clinical development and commercialization, including manufacturing, viral vector operations and analytics.

Journey Colab bags $3M from ‘moonshot’ fund to push new development model for psychedelic treatments

Mental health is an underfunded and underserved area, with tens of millions of Americans affected by mental illness and only about half of them getting treatment. Psychedelics like LSD and psilocybin, the chemical found in “magic” mushrooms, have the potential to become new treatments that help more patients, but today’s drug development model—not to mention the war on drugs—have hindered their progress.

error: Content is protected !!